TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: SEMS Placement Before Surgery in Unblocking Bile Duct in Patients With Periampullary Pancreatic Cancer With Severe Obstructive Jaundice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of operable peri-ampullary pancreatic cancer as determined by the Department of Surgery per their standard of care~* Serum bilirubin \> 10 mg/dl~* Adequate birth control~Exclusion Criteria:~* Patients with evidence of distant metastasis on computed tomography (CT) or magnetic resonance imaging (MRI)~* Patients anticipated to require vascular reconstruction~* Patients with cholangitis~* Patients for whom surgery is deemed inappropriate by surgeon~* Patients with bilirubin less than 10 mg/dL or greater than 20 mg/dL~* Patients who previously underwent biliary decompression for cholangitis by ERCP or percutaneous transhepatic cholangiography (PTC)~* Patients with low performance score (Karnofsky performance status scale \< 50)~* Patients with known preexisting liver disease with associated elevated bilirubin~* Patients who are pregnant or actively breast feeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SEMS (Type: EXPERIMENTAL): Patients undergo Endoscopic Retrograde Cholangiopancreatography (ERCP) with Self Expanding Metal Stents (SEMS) placement before standard of care surgical resection.
- Standard of care surgical resection (Type: ACTIVE_COMPARATOR): Patients undergo standard of care surgical resection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Biventricular Pacing After Cardiopulmonary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LV ejection fraction \< 41%~* QRS duration \> 99 msec~Or:~* Mitral and Aortic Valve Repair or Replacement~Exclusion Criteria:~* Congenital Heart Disease~* Intracardiac Shunts~* Preoperative Pacing for Heart Block (2nd or 3rd degree) or Sinus Bradycardia~* Heart Rate \> 120 beats per min after Cardiopulmonary Bypass~* Preoperative Atrial Fibrillation~* Previous Cardiac Surgery~* Inability to undergo biventricular pacing prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biventricular Pacing (Type: ACTIVE_COMPARATOR): After weaning from bypass, patients received temporary biventricular pacing for 24 hours. Values obtained from optimization testing determined pacemaker settings (AVD, VVD, heart rate).
- Standard of Care (Type: ACTIVE_COMPARATOR): No continuous pacing occurred about surgery. Patients underwent optimization testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients (cognitive interviews)~* Aged 18 years or over~* Reside in the US or Canada~* Have been diagnosed with NETs by a healthcare professional (based on self-report and confirmed via data quality checks)~* Have any SSA treatment experience in the past 2 years~* Be fluent in spoken and written English~* Have read, understood, and consented to participate in the study~* Be able to complete the survey on a standard-sized tablet device (minimum 10 inches), laptop, or desktop computer~* Be able and willing to screenshare with the interviewer~Patients (online survey and DCE)~* Aged 18 years or over~* Reside in the US or Canada~* Have been diagnosed with NETs by a healthcare professional (based on self-report and confirmed via data quality checks)~* Have any SSA treatment experience in the past 2 years~* Be fluent in spoken and written English~* Have read, understood, and consented to participate in the study~* Be able to complete the survey on a standard-sized tablet device (minimum 10 inches), laptop, or desktop computer~* Have not participated in the cognitive interviews~Nurses (cognitive interviews)~* Reside in the US or Canada~* Nurse with at least 12 months experience caring for patients with NETs~* Have administered at least one long-acting SSA injection to a patient with NETs in the past 12 months~* Be fluent in spoken and written English~* Have read, understood, and consented to participate in the study~* Be able to complete the survey on a standard-sized tablet device (minimum 10 inches), laptop, or desktop computer~* Be able and willing to screenshare with the interviewer~Nurses (online survey and DCE)~* Reside in the US or Canada~* Nurse with at least 12 months experience caring for patients with NETs~* Have administered at least one long-acting SSA injection to a patient with NETs in the past 12 months~* Be fluent in spoken and written English or Canadian French~* Have read, understood, and consented to participate in the study~* Be able to complete the survey on a standard-sized tablet device (minimum 10 inches), laptop, or desktop computer~* Have not participated in the cognitive interviews~Exclusion Criteria:~* No access to internet

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the pancreatic head~* Age ≥ 18 years~* Signed informed consent~* ECOG performance status of 0-2~Exclusion Criteria:~* Curative resection is not feasible or presence of metastatic disease~* Patients not eligible for surgery (ASA ≥ 4)~* Participation in an other clinical trial~* Unable or unwilling to sign the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant RTx (Type: EXPERIMENTAL): None
- Surgery (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neuromuscular Re-eduaction, Exercise and Electric Dry Needling vs. Neuromuscular Re-education and Exercise for Stress Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 35 - 75 years~2. Female~3. Meet the diagnosis of stress urinary incontinence - urine leakage with increased abdominal pressure from laughing, sneezing, coughing, or other physical stressors on abdominal cavity and bladder~Exclusion Criteria:~1. Urge urinary incontinence or mixed urinary incontinence~2. Greater than second degree prolapse~3. Previous surgical intervention related to female anatomy~4. Urinary tract infection~5. Unable to participate in movement such as walking, stair climbing, or resistance training~6. Taking medication that impacts bladder function~7. Serious cardiovascular, cerebral disease, psychiatric disorder, cognitively impaired, injury of cauda equine, and/or myelopathy~8. Pregnancy~9. Sacral nerve stimulator implanted~10. Cardiac pacemaker, metal allergy, or severe needle phobia

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Electric DN, NM Re-ed, Exercise (Type: EXPERIMENTAL): None
- NM Re-ed and Exercise (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~≥ 50 years of age or older at the time of enrollment~Willing to sign the informed consent form~Must have 2 occurrences from among the below parameters of diabetes mellitus (PDMs) in past 90 days measured in outpatient setting (not in urgent care, emergency room or while inpatient):~FBG ≥126mg/dl HbA1c ≥6.5% RBG ≥ 200mg/dl 2-hour post-glucose ≥200mg/dl (OGTT)~Must have had glycemic parameter measured in 3-18 months prior to screening that did NOT meet DM criteria~Must be willing to provide several tubes of blood without endangering health~No history of pancreatic cancer or other known pancreatic neoplasia~No active cancers within the past 5 years (with the exception of non-melanoma skin cancers resolved/treated \> 1 year prior to enrollment and in situ cancers)~Exclusion Criteria:~Prior DM diagnosis~Met criteria for DM ≥91 days prior to enrollment (patients with prior gestational diabetes that has resolved are NOT acceptable to enroll)~Carried a DM diagnosis or used anti-DM medications at a time greater than or equal to 91 days prior to enrollment~Any known pancreatic lesions (aside from diabetes)~Received cancer treatment within the past 5 years (with the exception of treatment of non-melanoma skin cancer), carrying a current cancer diagnosis, and/or being investigated for suspicion of past cancer recurrence.~Current chronic or acute oral steroid use~History of intra-articular steroid injections (\<1 week) of the qualifying DM blood test (allowed exception: nasal, topical, oral budesonide)~Any surgery requiring general anesthesia within 2 months of collection~Local anesthetic (including dental novocaine) within 1 week of collection~History or presence of HIV/AIDs, Hepatitis A or E within the past five years, TB, any kind of prion disorder (e.g., CJD)~Blood transfusion within 1 month~Organ transplant recipient~Currently pregnant, or pregnancy within last 12 months~Receipt of systemic immunomodulation therapy within past 12 months~Significant medical condition that in the site investigator's opinion would compromise the subject's ability to tolerate study interventions

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pancreatic Cancer Signal Detection = Detected (Type: OTHER): Subjects with test results detected will undergo MRI/Imaging
- Pancreatic Cancer Signal Detection = Not Detected (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ligasure II: Standard Stapling Versus Ligasure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years~* Patients scheduled for thoracotomy, lobectomy or bilobectomy~* Patients must give informed consent~Exclusion Criteria:~* Patient is unwilling or unable to provide informed consent~* Patients who can not tolerate thoracotomy~* Patients who require extensive dissection to release adhesions which may result in air leak and/or bleeding unrelated to the quality of the parenchymal seal achieved by the devices in question~* Patients with no parenchymal bridge between lobes; 100% complete fissure.~* Patients with complete incomplete fissure with a thickness \> 1.5 cm measure intraoperatively

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LigaSure (Type: EXPERIMENTAL): * Arm 1~* Patients undergoing lung surgery
- Automatic Staplers (Type: ACTIVE_COMPARATOR): * Arm 2~* Patients undergoing lung surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Victim of a traumatic event leading to personal injury~* Patient experienced a feeling of intense fear, hopelessness, or horror during the course of the event or immediately afterward~* Positive screen on the ASDS (for inclusion in the randomization phase); a total ASDS score of ≥ 37 (including a dissociative score of ≥ 9) will be counted as a positive screen.~Exclusion Criteria:~* Age \< 18~* Pregnant women, lactating women, or women not using acceptable form of birth control~* Epilepsy or head trauma resulting in seizures~* Current or historical schizophrenia, bipolar disorder, mental retardation, OCD, eating disorders, dementia, delirium, or self-injurious behavior~* Current/previously diagnosed PTSD~* History of hypersensitivity to sertraline~* Trauma occurring \> 7 days prior to likely first treatment in the randomization phase of the trial.~* Unable to provide informed consent for participation in the study protocol.~* Patient at high risk of recurrent bleeding despite surgical stabilization~* Patient with a history of serotonin syndrome~* Patient non-fluent in English~* Patient currently prescribed an antidepressant (any SSRI, SNRI, TCA, MAOI, mirtazapine, or trazodone in excess of 100mg per day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sertraline (Type: EXPERIMENTAL): Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age \>65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Supplementation Effects on Rehabilitation Outcomes in Rotator Cuff Pathology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18-65 years old~* Diagnosed with rotator cuff injury that will not be treated surgically~Exclusion Criteria:~* Have received a previous injection therapy (platelet-rich plasma or corticosteroid injection) within previous 6 months~* Have used the following supplements in the previous 2 weeks: Vitamin C or D, or protein supplements~* Have poorly controlled type I or type II diabetes (HgB A1C \> 9.5%) or renal insufficiency (GFR \< 60 ml/min).~* Have an inability to participate in rehabilitation exercises.~* Are diagnosed with arthritis, rheumatoid arthritis, or any other autoimmune or rheumatologic disease~* Have musculoskeletal pathology in a neighboring joint or structure~* Have an allergy to any component of the nutritional supplement~* Are consuming warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (maltodextrin) (Type: PLACEBO_COMPARATOR): Maltodextrin
- Multi-Nutrient Blend (Type: ACTIVE_COMPARATOR): Blend of vitamins, minerals, and amino acids, given twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluorescence Imaging in Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 years or older will be considered eligible.~* Patients with head and neck malignancies, such as melanoma, non-melanoma cutaneous malignancies, or oral cavity squamous cell carcinoma. Patients with central neck pathology including thyroid neoplasms, parathyroid neoplasms, and laryngeal neoplasms undergoing surgical resection.~  * Candidates for sentinel lymph node biopsy or central neck surgery~ * Newly diagnosed with clinically node negative head and neck cancer being staged with sentinel lymph node biopsy.~* Not pregnant or breast feeding.~* Able to understand and willing to sign an IRB-approved written informed consent document.~* Able to understand written or spoken English.~Exclusion Criteria:~* History of allergy to iodide drugs or shellfish (iodine allergy)~* Pregnant or breast feeding~* Do not fit age criteria~* Prisoners~* Unable to provide written consent~* Contraindications for surgery~  \*Presence of uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of the head and neck, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Receiving any other investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Goggle Imaging (Type: EXPERIMENTAL): -Patient will then be taken to the operating room for this surgical procedure. Prior to starting the operation, the patient will undergo injection of ICG around the tumor per standard techniques while in the operating room. Those undergoing intraoperative visualization of parathyroid glands will not have any administration of ICG as these glands autofluoresce. Patients will then undergo the standard SLN biopsy procedure (those undergoing parathyroid visualization will not undergo this). The surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance or parathryroid visualization. After this is performed, the goggle system will be removed and the procedure will be completed per normal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metformin in Non Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with pathologic diagnosis of lung NSCLC or squamous cell carcinoma.~2. Patients are to be treated with hypofractionated RT.~3. Patient is not a surgical candidate due to medical comorbidities determined by a thoracic surgeon or patient refusal~4. Patient plans to receive treatment at MD Anderson~5. Patients must sign informed consent~6. Patient must have adequate renal function within 30 days prior to registration, defined as serum creatinine within normal institutional limits or creatinine clearance at least 60 ml/min~Exclusion Criteria:~1. Patient has: random glucose \>200 mg/dl or is taking an oral hypoglycemic agent or insulin at the time of study entry~2. Patient has a history of lactic acidosis, chronic kidney disease or a creatinine \>/= 1.2 mg/dl~3. Women who are pregnant or breast feeding, as treatment involves unforeseeable risks to the participant, embryo, fetus, or nursing infant~4. Patients with history of allergic reaction to metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stereotactic body Radiotherapy (SBRT) + Metformin (Type: EXPERIMENTAL): Participants randomized to Metformin treatment receive Metformin for 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Metformin administered at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week. SBRTdelivered per standard of care practice.
- Stereotactic Body Radiotherapy (SBRT) + Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to placebo treatment 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day. SBRT delivered per standard of care practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues